Source: ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Macha Tetart, Frederic Wallet, Maeva Kyheng, Sylvie Leroy, Thierry Perez, Olivier Le Rouzic, Benoit Wallaert, Anne Prevotat. Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis. ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019

Member's Comments

No comment yet.

Related content which might interest you: Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Achromobacter xylosoxidans strains with shared genotype among patients attending a cystic fibrosis (CF) rehabilitation centre Source: Eur Respir J 2005; 26: Suppl. 49, 596s Year: 2005 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017 Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung Source: Eur Respir J , 49 (4)  1602108; DOI: 10.1183/13993003.02108-2016 Year: 2017 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Impact of Aspergillus fumigatus infection on lung function in children with cystic fibrosis Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004 Treatment of Burholderia cepacia infection in patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 539s Year: 2001 DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002